Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.43 |
| ▸ | USP7 | Q93009 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455970 | 0.82 | MAP4K4 (0.42) | DGAT1MAP4K4LRRK2USP7CHEK2 | |
| SCHEMBL8365565 | 0.77 | NPC1 (0.50) | NPC1RAB9A | |
| SCHEMBL16455947 | 0.75 | MAP4K4 (0.47) | DGAT1MAP4K4LRRK2USP7KCNH2 | |
| SCHEMBL16455935 | 0.72 | KIF11 (0.45) | DGAT1MAP4K4NPC1RAB9A | |
| SCHEMBL16456297 | 0.72 | MAP4K4 (0.61) | MAP4K4LRRK2USP7CHEK2FYN | |
| SCHEMBL16455936 | 0.72 | LRRK2 (0.51) | DGAT1MAP4K4LRRK2USP7KCNH2 | |
| SCHEMBL16456299 | 0.70 | MAP4K4 (0.52) | MAP4K4LRRK2USP7CHEK2FYN | |
| SCHEMBL16455975 | 0.70 | KIT (0.41) | — | |
| SCHEMBL16455942 | 0.68 | DYRK1A (0.46) | DGAT1MAP4K4LRRK2USP7CHEK2 | |
| SCHEMBL13097048 | 0.67 | NOS3 (0.44) | MAP4K4NPC1RAB9AMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | DGAT1 3659/4885MAP4K4 560/4885LRRK2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.